Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: • Less than…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
Discover hidden China stock gems in our weekly newsletter